cas 65766-32-7|| where to buy 4-Chloro-6-(methylamino)pyrimidine

Nombre del producto:4-Chloro-6-(methylamino)pyrimidine

IUPAC Name:6-chloro-N-methylpyrimidin-4-amine

Unidad de embalaje	Stock disponible	Precio($)
CM119066-25g	in stock	ȡȡ
CM119066-100g	in stock	ƥȯȐ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 65766-32-7 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :65766-32-7; Fórmula molecular:C5H6ClN3; Punto de fusión:-; Código de sonrisas:CNC1=CC(Cl)=NC=N1; Densidad:

: Número de catálogo:CM119066; Peso molecular:143.57; Punto de ebullición:; Nº Mdl:MFCD09702146; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Infigratinib; Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.